Cagent Vascular
WAYNE, PA, United States · Healthcare, Health Care · 50 employees
Cagent Vascular has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology.
Funding history
- Series D — $41.0M — May 2026
- Funding Round — $15.0M — Feb 2025
- Series C — $30.0M — Feb 2024
- Series C — $30.0M — Feb 2024
- Venture - Series Unknown — $28.7M — Feb 2024
Recent signals
- May 19, 2026: Raised $41.0M in Series D
- Apr 03, 2025: Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family
- Mar 04, 2025: Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Lead Commercial Strategy
- Feb 20, 2025: Raised $15.0M in Funding Round
- Jan 28, 2025: Launched Cagent Vascular, Inc. launches the POINT FORCE Registry to evaluate the safety and efficacy of the Serranator® PTA Serration Balloon Catheter.
- May 07, 2024: Cagent Vascular Appoints Brian Walsh as Chief Executive Officer
- Feb 21, 2024: Raised $30.0M in Series C
- Feb 20, 2024: Raised $30.0M in Series C
See plans & pricing → Track Cagent Vascular’s funding, hiring, and signals — with verified contacts — on Fundz.